This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from the Medical College of Georgia, Augusta, performed a retrospective analysis of 226 patients with sickle cell disease (SCD) aged 16 to 68 years of age who were treated with hydroxyurea (HU) over a 15-year period. The investigators compared the characteristics of the 38 patients who died during this period with those of surviving patients. Of these 38 patients, 26 were on HU therapy at the time of death, and 12 were not compliant with therapy. Four patients died of causes unrelated to SCD. Of the 34 patients who died of sickle cell–related causes, 12 died of acute chest syndrome (ACS), 5 of multiorgan failure, 4 of stroke, 2 of end-stage renal disease, and 1 each of cardiac arrest, sepsis, cardiac arrhythmia, and pulmonary embolism. In 7 patients, the precise cause of death could not be determined. Deceased and surviving patients did not differ significantly with regard to average HU dose, duration of HU therapy, baseline hemoglobin F (Hb F), or maximum Hb F response. Men and women had equivalent survival rates.
The deceased group of patients was older (30.6 …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.